Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amgen, Inc. (AMGN) vs Gogoro Inc (GGR) Price & Performance

Amgen, Inc.Trade
Gogoro IncTrade

Price performance (Past 24H)

Key statistics

Amgen, Inc. vs Gogoro Inc — how do they compare? Amgen, Inc. trades at $416.99 (market cap $224.14B), while Gogoro Inc trades at $2.51 (market cap $52.19M). The key difference: Amgen, Inc. is far larger — about 4294.7× Gogoro Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Gogoro Inc pays none. Which is the better fit depends on your goals.

AMGNGGR
Market Cap
$224.14B$52.19M
Sector
HealthTechnology
52-Week High
$417.20$7.50
52-Week Low
$271.18$2.55
Enterprise Value
$267.45B$354.63M
Dividend Yield
2.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amgen, Inc.

AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.

Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.

Gogoro Inc

GGR trades at $2.63, up 1.94% today, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $79.97 million on $281.48 million revenue in 2025, with negative margins and cash flow, though 2026 projections show improvement. Analyst consensus is entirely hold, reflecting caution amid ongoing losses.

Outlook remains challenging with persistent losses and negative cash flow, but low P/S and P/B ratios may attract value investors if operational improvements materialize. Key risks include execution on profitability, competitive pressures, and reliance on future growth initiatives to achieve sustained positive earnings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amgen, Inc.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Read more on AMGN

About Gogoro Inc

Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.

Read more on GGR